November - 2021

top of page

FDA Grants Profounda Orphan DD Approval for treatment of invasive candidiasis with Miltefosine

FDA Grants Profounda Orphan Drug Designation Approval for treatment of invasive candidiasis with Miltefosine - Invasive candidiasis is an...

Featured Posts

CDC Video showing N.Fowleri

CDC Video showing N.Fowleri

AK and miltefosine

AK and miltefosine

4th Patient in the USA to survive the deadly Amoeba Parasite

4th Patient in the USA to survive the deadly Amoeba Parasite

Colombia: Leishmaniasis outbreak affects 80 in Norte de Santander

Colombia: Leishmaniasis outbreak affects 80 in Norte de Santander

Recent Posts

FDA Grants Profounda Orphan DD Approval for treatment of invasive candidiasis with Miltefosine

ID WEEK in SAN DIEGO

CDC Video showing N.Fowleri

FDA Grants Profounda Inc. Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis

AK and miltefosine

Five little-known diseases to watch out for in 2017

IDSA, ASTMH release leishmaniasis guidelines following increase in US cases

Deadly Parasitic Disease Finding Its Way to US Soil

Epidemiologic Correlates of Mortality among Symptomatic Visceral Leishmaniasis Cases: Findings from

4th Patient in the USA to survive the deadly Amoeba Parasite

Archive

Search By Tags

Follow Us

Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO

bottom of page